Mounjaro (Tirzepatide) is a unique medication that acts on two hormone receptorsGLP-1 and GIP
Research has shown that estrogen deficiency (as in menopause) leads to decreased GLP-1 secretion, and estrogen replacement reverses this effect [3]
Gwern Supplementary Appendix (Peer-Reviewed Study Supplement NEJM) Supplement to: Jastreboff AM, Kaplan LM, Fras JP, et al
BOOK FREE CONSULTATION IntraVita classifies its products as IV nutrients that are used for supplementation purposes only and not to treat any medical conditions
By stimulating these receptors, Tirzepatide enhances insulin sensitivity and reduces insulin resistance
The Mounjaro Savings Card offers $25 per month for patients with a type 2 diabetes diagnosis and commercial insurance, with a $1,950 annual cap